Tonke Van Bragt

Title: The Innovative Contributions of Tonke Van Bragt

Introduction

Tonke Van Bragt is a notable inventor based in Boxtel, Netherlands. He has made significant contributions to the field of medicine, particularly in the treatment of immune thrombocytopenia (ITP). His innovative approach has the potential to improve the lives of many patients diagnosed with this condition.

Latest Patents

Tonke Van Bragt holds a patent for "Compositions and methods for treating immune thrombocytopenia." This patent discloses a method for treating human subjects diagnosed with ITP. The method involves administering a human neonatal Fc receptor (hFcRn) antagonist, which may be combined with standard-of-care ITP treatments. In certain embodiments, the hFcRn antagonist used is efgartigimod (ARGX-113). The standard treatments may include corticosteroids, immunosuppressants, and thrombopoietin receptor (TPO-R) agonists. He has 1 patent to his name.

Career Highlights

Tonke Van Bragt is associated with Argenx Bv, a company known for its innovative approaches in the field of immunology. His work at Argenx has positioned him as a key player in the development of new therapies for autoimmune diseases.

Collaborations

He has collaborated with notable colleagues such as Hans De Haard and Peter Ulrichts, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Tonke Van Bragt's contributions to the field of medicine through his patent for treating immune thrombocytopenia highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic options for patients.